[HTML][HTML] The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretation

K Webster, D Cella, K Yost - Health and quality of life outcomes, 2003 - Springer
Abstract The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement
System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the …

[HTML][HTML] Outcome measures in clinical trials for multiple sclerosis

CEP van Munster, BMJ Uitdehaag - CNS drugs, 2017 - Springer
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …

[PDF][PDF] Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota

F Cignarella, C Cantoni, L Ghezzi, A Salter, Y Dorsett… - Cell metabolism, 2018 - cell.com
Multiple sclerosis (MS) is more common in western countries with diet being a potential
contributing factor. Here we show that intermittent fasting (IF) ameliorated clinical course and …

[图书][B] Руководство по исследованию качества жизни в медицине

AA Novik - 2002 - books.google.com
То радиционно критериями эффективности лечения в клинических исследованиях
являются физикальные данные и лабораторные показатели. Так, эффективность …

[图书][B] Шкалы, тесты и опросники в неврологии и нейрохирургии

А Белова - 2020 - books.google.com
Книга посвящена вопросам использования опросников, тестов и шкал для оценки
состояния неврологических больных и определения эффективности лечения …

The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure

J Hobart, D Lamping, R Fitzpatrick, A Riazi… - Brain, 2001 - academic.oup.com
Abstract Changes in health policy have underlined the importance of evidence-based
clinical practice and rigorous evaluation of patient-based outcomes. As patient-based …

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)

JC Hobart, A Riazi, DL Lamping, R Fitzpatrick… - Neurology, 2003 - AAN Enterprises
Objective: To develop a patient-based measure of walking ability in MS. Methods: Twelve
items describing the impact of MS on walking (12-Item MS Walking Scale [MSWS-12]) were …

Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing

AJ Mitchell, J Benito-León, JMM González… - The Lancet …, 2005 - thelancet.com
Health-related quality of life (HRQoL) has been more intensively studied in multiple sclerosis
(MS) than in any other neurological disorder. Traditional medical models of impairment and …

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

L Kappos, CH Polman, MS Freedman, G Edan… - Neurology, 2006 - AAN Enterprises
Objective: To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b
treatment in patients with a first clinical event suggestive of multiple sclerosis (MS)(clinically …

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the …

L Kappos, MS Freedman, CH Polman, G Edan… - The Lancet, 2007 - thelancet.com
Background Several controlled studies provide evidence that treatment with interferon beta
in patients with a first event suggestive of multiple sclerosis (MS) delays conversion to …